{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:33:44Z","timestamp":1790354024238,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010104","name":"Zhengzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["242102310112"],"award-info":[{"award-number":["242102310112"]}],"id":[{"id":"10.13039\/100010104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related disorders, but long-term use has been increasingly associated with an elevated risk of osteoporosis. However, the underlying molecular mechanisms and specific targets of PPIs-induced bone loss remain poorly understood. This study aimed to explore the molecular mechanisms and key genes of PPIs-induced osteoporosis using network toxicology, molecular docking, and molecular dynamics simulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified common targets of four widely used PPIs (omeprazole, lansoprazole, pantoprazole, and rabeprazole) and osteoporosis by screening large-scale biological databases. A protein-protein interaction network was constructed, and key hub genes were determined based on topological parameters such as degree, betweenness centrality, and closeness centrality. Enrichment analysis was performed to explore the biological processes, cellular components, molecular functions, and KEGG pathways associated with the overlapping targets. Molecular docking was conducted to evaluate the binding affinities between PPIs and their potential targets, and molecular dynamics simulations were employed to assess the stability of these interactions over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 35 potential targets for omeprazole-induced osteoporosis, 39 for lansoprazole, 29 for pantoprazole, and 29 for rabeprazole. Topological analysis of the protein-protein interaction networks revealed the hub genes for each PPI: epidermal growth factor receptor (EGFR) for omeprazole, estrogen receptor 1 (ESR1) for lansoprazole, EGFR for pantoprazole, and Proto-oncogene tyrosine-protein kinase SRC for rabeprazole. Molecular docking demonstrated strong and stable binding affinities between PPIs and their respective targets, with binding energies all below \u22125\u00a0kcal\/mol. Molecular dynamics simulations confirmed the structural stability of these complexes, characterized by low root mean square deviation and root mean square fluctuation values and consistent hydrogen bond formation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study identified EGFR, ESR1, and SRC as key regulatory genes in PPIs-induced osteoporosis, highlighting their roles in bone metabolism. The stable interactions between PPIs and these targets suggest their involvement in bone loss, providing a foundation for future experimental validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1592048","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:39:51Z","timestamp":1747028391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Exploring the mechanisms and targets of proton pump inhibitors-induced osteoporosis through network toxicology, molecular docking, and molecular dynamics simulations"],"prefix":"10.3389","volume":"16","author":[{"given":"Yaqi","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110769","DOI":"10.1016\/j.ygeno.2023.110769","article-title":"Systems genetics and bioinformatics analyses using ESR1-correlated genes identify potential candidates underlying female bone development","volume":"116","author":"Bajpai","year":"2024","journal-title":"Genomics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"dgae598","DOI":"10.1210\/clinem\/dgae598","article-title":"Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality","author":"Bioletto","year":"2024","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1172\/JCI116032","article-title":"Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice","volume":"90","author":"Boyce","year":"1992","journal-title":"J. Clin. Investigation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20488","DOI":"10.1074\/jbc.M112.447250","article-title":"Epidermal growth factor receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing early growth response 2 (EGR2) expression","volume":"288","author":"Chandra","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.ajpath.2021.05.011","article-title":"The role of estrogen in insulin resistance: a review of clinical and preclinical data","volume":"191","author":"De Paoli","year":"2021","journal-title":"Am. J. Pathology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/RMHP.S223118","article-title":"The association between prolonged proton pump inhibitors use and bone mineral density","volume":"12","author":"Fattahi","year":"2019","journal-title":"Risk Manag. Healthc. Policy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4183\/aeb.2023.349","article-title":"Insulin resistance and pathogenesis of postmenopausal osteoporosis","volume":"19","author":"Greere","year":"2023","journal-title":"Acta Endocrinol. Buchar. Rom. 2005"},{"key":"B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic and Clin. Pharmacol. and Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bone.2016.03.016","article-title":"Estrogen receptors alpha and beta in bone","volume":"87","author":"Khalid","year":"2016","journal-title":"Bone"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1038\/onc.2008.156","article-title":"A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation","volume":"27","author":"Lin","year":"2008","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41418-017-0054-7","article-title":"EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation","volume":"25","author":"Linder","year":"2018","journal-title":"Cell Death Differ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11137","DOI":"10.1096\/fj.201900436RR","article-title":"The role of EGFR signaling in age-related osteoporosis in mouse cortical bone","volume":"33","author":"Liu","year":"2019","journal-title":"FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased c-Src expression enhances osteoblast differentiation and bone formation","volume":"151","author":"Marzia","year":"2000","journal-title":"J. Cell Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/1062936X.2012.657237","article-title":"The impact of network biology in pharmacology and toxicology","volume":"23","author":"Panagiotou","year":"2012","journal-title":"SAR QSAR Environ. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug Discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","article-title":"Proton pump inhibitor use: systematic review of global trends and practices","volume":"79","author":"Shanika","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"B19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2024.08.008","article-title":"Postmenopausal osteoporosis: a review of latest guidelines","volume":"53","author":"Subarajan","year":"2024","journal-title":"Endocrinol. Metabolism Clin. N. Am."},{"key":"B20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ Can. Med. Assoc. J. = J. de L'Association Medicale Can."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.3390\/ijms24065814","article-title":"Hormone-related and drug-induced osteoporosis: a cellular and molecular overview","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1753-4887.2008.00015.x","article-title":"Proton pump-inhibiting drugs, calcium homeostasis, and bone health","volume":"66","author":"Wright","year":"2008","journal-title":"Nutr. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cbdd.14038","article-title":"Application of molecular dynamics simulation in biomedicine","volume":"99","author":"Wu","year":"2022","journal-title":"Chem. Biol. and Drug Des."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/med.22081","article-title":"Estrogen deficiency-mediated osteoimmunity in postmenopausal osteoporosis","volume":"45","author":"Yao","year":"2025","journal-title":"Med. Res. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2017.19344","article-title":"Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis","volume":"318","author":"Zhao","year":"2017","journal-title":"JAMA"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1592048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:39:52Z","timestamp":1747028392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1592048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":26,"alternative-id":["10.3389\/fphar.2025.1592048"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1592048","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"1592048"}}